Abstract 1501P
Background
The Gender differences in the clinical symptoms presentation (CSP) are known and already studied in many settings of medicine, such as Cardiology and Neurology. However, these differences have been studied less deeply in Oncology and Palliative Care. Our analysis focused on evluating how gender can affect the CSP in an integrated outpatient clinic between Radiotherapy and Palliative Care (RaP).
Methods
This is a monocentric, observational study carried out in the RaP integrated outpatient clinic in a Research Cancer Hospital (IRCCS, IRST - Meldola, Italy). Descriptive statistics were reported for each Edmonton Symptom Assessment System (ESAS) item, separately by gender. Additionally, a set of linear models were developed to predict ESAS items score. Multivariable linear model incorporated all other symptoms, clinical characteristics (e.g tumor location), and the sex variable to evaluate possible gender effects. All analyses were performed using R statistical software.
Results
212 patients were enrolled in the study between 2016 and 2020. Most of the symptoms showed significant gender differences. Specifically, the symptom "Pain” showed higer values in the male population (mean: M5.1 vs. F 4.4). Conversely, the symptom "Anxiety” showed higer values in the female population (mean. M 2.0 vs F 3.0). Finally, the "total symptom distress score” resulted in higer values in the female population (mean: M 23.0 vs F 25.4). Interestingly, the symptom "malaise” is the only that showed an almost perfect equity for all values (mean M1.9 vs F 2.0). The linear model aimed at assessing, ceteris paribus, report 0.9 additional points than females (p= 0.053). Conversely, keeping constant all other factors, females report 0.95 higer expression of anxiety (p=0.002).
Conclusions
The gender differences in the CSP and their distribution highligheted in our analysis are important in the new subfield of medicine called "Gender Medicine". Especially in palliative care, data relating to patients symptoms is necessary to reach the goal of the best supoportive care. Additional studeis will be necessary to improve our knowledge in this field.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
L. Tontini.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1502P - Sexual dysfunction and quality of life in rectal cancer
Presenter: Fatih Kus
Session: Poster session 10
1503P - Spiritual needs in cancer patients: A cross-sectional study
Presenter: Diego Toloi
Session: Poster session 10
1546P - Use of ESMO-MCBS Scorecards in supporting funding decisions in private insurance
Presenter: Samantha Field
Session: Poster session 10
1547P - Time from approval to reimbursement of new cancer and non-cancer drugs: A comparative analysis between the US, England, Germany, and Switzerland (2011-2022)
Presenter: Camille Glaus
Session: Poster session 10
1548P - Real-world impact of the platinum chemotherapy shortage on advanced cancer patients
Presenter: Jacob Reibel
Session: Poster session 10
1549P - Accelerating access to innovative oncology drugs: Insights from France's early access reform
Presenter: Tess Martin
Session: Poster session 10
1550P - Addressing uncertainties of clinical value and improving access for newly authorised indications through DRUG-Access Protocol (DAP)-like platforms: Joint collection and evaluation of real-world evidence
Presenter: Sahar van Waalwijk van Doorn-Khosrovani
Session: Poster session 10
1551P - Breakthrough therapy cancer drugs and indications with FDA approval: Development time, innovation, trials, clinical benefit, epidemiology, and price
Presenter: Christoph Michaeli
Session: Poster session 10
1552P - Regulatory approval of novel immunotherapy for lymphoid neoplasm in the US, EU, and Japan
Presenter: Kensuke Matsuda
Session: Poster session 10
1553P - Access to EMA approved drugs in Europe, disparities across a border
Presenter: Orla Fitzpatrick
Session: Poster session 10